ConvaTec Group Plc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jonathan Peter Mason
- Full Time Employees
- 10,910
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 20 Eastbourne Terrace London GL United Kingdom W2 6LG
- IPO Date
- Oct 31, 2016
- Website
- convatecgroup.com
- Similar Companies
- Business
- ConvaTec Group Plc develops, manufactures and markets medical products and technologies focused on managing chronic conditions including advanced wound care, ostomy care, continence and critical care, and infusion care; its portfolio encompasses advanced wound dressings and technologies for acute and chronic wounds from conditions such as diabetes, traumatic injury and burns; ostomy pouches, devices, accessories and personalized services for stoma patients ensuring comfort, security and skin protection; continence catheters and critical care solutions for urinary continence and patient dignity; and disposable infusion sets for insulin pump therapy in diabetes management, pain management and other therapies including partnerships with Medtronic's 780G extended wear infusion set, Tandem Mobi, Beta Bionics iLet and AbbVie's Parkinson's Neria Guard. The company operates in over 100 countries with primary markets in North America and Europe; employs approximately 10,000 people; was founded in 1978 as part of E.R. Squibb & Sons and is headquartered at 20 Eastbourne Terrace, London, England, United Kingdom. Recent developments include four key product launches or major geographic expansions in 2024 such as ConvaFoam, Esteem Body, GentleCath Air for Women and extended wear infusion sets; three acquisitions related to its Livramedom home services group in 2024 plus one small acquisition in France alongside approximately $90 million in earn-outs; increased R&D investment to 4.6% of sales and $122 million in capital expenditures emphasizing clinical and regulatory engagement; divestiture of low-margin hospital care, industrial sales and Russia operations completed by early 2025; and progression of seven additional products for launch in 2025 and 2026 including support for Mitsubishi Tanabe launches and diversification beyond diabetes.
Company News
JP Morgan says ConvaTec guidance looks increasingly secure ahead of trading update
Convatec Survey Challenges Assumptions About Leakage in Ostomy Care
Convatec Expands Cure™ Portfolio With Launch of Cure Aqua™, Bringing Greater Choice to People Who Catheterize
Convatec Group PLC (CNVVY) Q2 2026 Earnings Call Transcript
ConvaTec Group H1 Earnings Call Highlights
UK's Convatec expects higher second-half margin, launches $200 million buyback
Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non‑communicable Disease and Chronic Conditions
Convatec Group PLC (CNVVY) ConvaTec Group PLC, 4 Months Period Ending/ Trading Statement Call Transcript
Medical product maker Convatec warns of higher cost from Iran War
ConvaTec falls despite backing outlook
Convatec's Advanced Wound Care Innovation Leads the Industry at European Wound Management Association (EWMA) 2026
Convatec Group PLC (CNVVY) Analyst/Investor Day Transcript
Leading bank sees Convatec investor meting as credibility test for growth targets
Convatec Introduces Co-Branded eakin freeseal® Ostomy Seal in North America, Expanding the ESENTA™ Family of Accessories
Convatec Group PLC (CNVVY) Q4 2025 Earnings Call Transcript
ConvaTec Group (OTCMKTS:CNVVY) Trading Up 1.6% – What’s Next?
FTSE 100 Live: London stocks pare gains; US futures point to mixed start
FTSE 100 Live: London stocks off to a strong start after Dow hits new record
Artisan International Small-Mid Fund Q3 2025 Performance Review
ConvaTec Group PLC (CNVVY) 10 Months 2025 Sales/ Trading Statement Call Transcript